Wilkins CR, Zwicker JI, Derkach A, Burge M. Impact of romiplostim on overall survival in chemotherapy induced thrombocytopenia. Blood . 2023;142(suppl 1):801-802.
Blood · 2024
DOI: 10.1182/blood.2024024692 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, 2024. Hauptthemen laut MEDLINE: Thrombocytopenia, Thrombopoietin, Receptors, Fc, Recombinant Fusion Proteins.
Themen: Onkologische Pflege
Abstract (Originalsprache)
This American Society of Hematology annual meeting abstract has been retracted; please see Elsevier's Article Correction, Retraction and Removal Policy (Article withdrawal | Elsevier policy). This abstract has been retracted at the request of the Editors and the authors. The study’s authors conducted a reanalysis of their work, rematching the cohorts by including platelet count at the time of growth factor administration. They report that upon this reanalysis, both cohorts displayed similar survival, and thus the conclusions differed substantially and meaningfully from those stated in the abstract. To avoid any patient safety issues arising from this incorrect conclusion, the authors request retraction. All authors approve the retraction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
(2024). Wilkins CR, Zwicker JI, Derkach A, Burge M. Impact of romiplostim on overall survival in chemotherapy induced thrombocytopenia. Blood . 2023;142(suppl 1):801-802. Blood. https://doi.org/10.1182/blood.2024024692
Vancouver
Wilkins CR, Zwicker JI, Derkach A, Burge M. Impact of romiplostim on overall survival in chemotherapy induced thrombocytopenia. Blood . 2023;142(suppl 1):801-802. Blood. 2024. doi:10.1182/blood.2024024692
BibTeX
@article{euvimed2024,
title = {Wilkins CR, Zwicker JI, Derkach A, Burge M. Impact of romiplostim on overall survival in chemotherapy induced thrombocytopenia. Blood . 2023;142(suppl 1):801-802},
journal = {Blood},
year = {2024},
doi = {10.1182/blood.2024024692}
}
EUVIMED